Researchers Use CRISPR to Epigenetically Alter Disease Phenotypes in Mice

NEW YORK (GenomeWeb) – A team led by researchers at the Salk Institute has developed a CRISPR-Cas9 genome editing system that epigenetically activates target genes without causing DNA double-strand breaks (DSBs). As they reported today in Cell, the investigators used the new system to treat diabetes, acute kidney disease, and muscular dystrophy in mouse models.